Matthew P Wilson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8259708/publications.pdf

Version: 2024-02-01

1307594 1281871 11 598 7 11 citations g-index h-index papers 11 11 11 1035 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Host-Microbe Co-metabolism Dictates Cancer Drug Efficacy in C.Âelegans. Cell, 2017, 169, 442-456.e18.	28.9	198
2	Disorders affecting vitamin B ₆ metabolism. Journal of Inherited Metabolic Disease, 2019, 42, 629-646.	3.6	143
3	Mutations in PROSC Disrupt Cellular Pyridoxal Phosphate Homeostasis and Cause Vitamin-B6-Dependent Epilepsy. American Journal of Human Genetics, 2016, 99, 1325-1337.	6.2	118
4	<i>PDXK</i> mutations cause polyneuropathy responsive to pyridoxal 5â€2â€phosphate supplementation. Annals of Neurology, 2019, 86, 225-240.	5.3	54
5	An LC–MS/MS-Based Method for the Quantification of Pyridox(am)ine 5′-Phosphate Oxidase Activity in Dried Blood Spots from Patients with Epilepsy. Analytical Chemistry, 2017, 89, 8892-8900.	6.5	24
6	The evolving genetic landscape of congenital disorders of glycosylation. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 129976.	2.4	24
7	Quality and stability of extemporaneous pyridoxal phosphate preparations used in the treatment of paediatric epilepsy. Journal of Pharmacy and Pharmacology, 2017, 69, 480-488.	2.4	14
8	CAMLG-CDG: a novel congenital disorder of glycosylation linked to defective membrane trafficking. Human Molecular Genetics, 2022, , .	2.9	7
9	Lack of NKG2D in MAGT1-deficient patients is caused by hypoglycosylation. Human Genetics, 2022, 141, 1279-1286.	3.8	6
10	SLC37A4 DG : Second patient. JIMD Reports, 2021, 58, 122-128.	1.5	5
11	Active site variants in STT3A cause a dominant type I congenital disorder of glycosylation with neuromusculoskeletal findings. American Journal of Human Genetics, 2021, 108, 2130-2144.	6.2	5